US · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 0.30 against a street estimate of 0.30 — a beat of 0.0%.
Analysts rate Kiniksa Pharmaceuticals Ltd a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $98.00.
CONFIDENT ARCALYST Q2 revenue hit $243.6M (+55% YoY, +$29M QoQ), largest quarterly growth since launch. KPL-387 Phase III initiated with monthly dosing. Raised FY26 guidance to $980–995M. 21% penetration in multiple-recurrence population signals runway. Q2 2026 No geographic breakouts provided. Analysts probed growth sustainability (AI, DTC, ACC dissemination cited), KPL-387 differentiation (monthly dosing & 75% patient preference highlighted), and first-recurrence uptake (20% of Q2 Rx, growing). Management deflected sales-force headcount question; emphasized no one-size-fits-all approach. 2026-07-28…
Full summary in the app.
| Fund | Stake |
|---|---|
| FMR Inc | 8.75% |
| Rubric Capital Management LP | 4.81% |
| Baker Bros Advisors LP | 3.62% |
| TANG CAPITAL MANAGEMENT LLC | 2.90% |
| Vanguard Portfolio Management, LLC | 2.26% |
| Acadian Asset Management LLC | 1.71% |
| Vanguard Capital Management, LLC | 1.71% |
| Morgan Stanley - Brokerage Accounts | 1.28% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC - Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Product Revenue (6 months ended June 30, 2026): $457.9 million | 2026-07-28 |
| Results announced · Q3 2026 KINIKSKA PHARMACEUTICALS - Q2 2026 SUMMARY HEADLINE NUMBERS • Q2 2026 total revenue: $243.6 million vs. $156.8 million in Q2 2025 (+55% YoY) • Q2 20 | 2026-07-28 |
| Shareholder vote results · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – SHAREHOLDER MEETING SUMMARY HEADLINE NUMBERS • Annual Meeting held May 29, 2026 with quorum present • T | 2026-05-29 |
| Material agreement · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC – FORM 8-K SUMMARY May 21, 2026 --- BUSINESS & SEGMENT HIGHLIGHTS • Kiniksa Pharmaceuticals Internationa | 2026-05-26 |
| Board / officer change · Q2 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC - DOCUMENT SUMMARY HEADLINE NUMBERS • Filing Date: April 30, 2026 (Form 8-K - Current Report) • Company: | 2026-05-01 |
| Quarterly report · Q1 2026 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC - Q1 2026 SUMMARY HEADLINE NUMBERS • Total Revenue (Q1 2026): $214.3 million vs. $137.8 million (Q1 2025) | 2026-04-28 |
| Proxy statement · Q2 2026 KINIKSKA PHARMACEUTICALS INTERNATIONAL, PLC — PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Re-elect three Class II Directors—Stephen | 2026-04-16 |
| Annual report FY2025 KINIKSKA PHARMACEUTICALS INTERNATIONAL, PLC – FORM 10-K SUMMARY HEADLINE NUMBERS • Public company trading on Nasdaq as KNSA (Class A ordinary shares | 2026-02-24 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Kiniksa Pharmaceuticals Ltd — free to start.
Google PlayApp StoreData updated 2026-09-18.